Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 183 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

 		Sickle Cell Disease United States NCT06155500

A Long-term Safety Study in Brazilian Patients With a Diagnosis of Spinal Muscular Atrophy Treated With Zolgensma

 		Spinal Muscular Atrophies Brazil NCT06019637

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

 		Relapsing-Remitting Multiple Sclerosis Phase4 Canada
United States 		NCT05090371

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

 		Follicular Lymphoma (FL) Phase3 Australia
Austria
Canada
Czechia
Hungary
Poland
Romania
Singapore
Slovakia
South Korea
Spain
Taiwan
United States
View All
 NCT05888493

A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.

 		Glioblastoma Phase1 France
Spain
Switzerland
United States
View All
 NCT05109728

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

 		Prostatic Neoplasms, Castration-Resistant Phase1 Australia
South Africa 		NCT04597411

Study of Out of Specification for Tisagenlecleucel

 		B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma Phase3 Japan NCT04094311

Kesimpta Pregnancy and Infant Safety Study Using Real World Data

 		Multiple Sclerosis Switzerland NCT06156683

Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

 		Multiple Sclerosis United States NCT04933552

A Prospective Observational Study to Describe Clinical Outcomes, Treatment Patterns, Patients Characteristics Among Patients With HR+/HER2- Advanced BC Initiating Treatment With Risarg®, Piqray®, Endocrine Therapy or Chemotherapy in Routine Clinical Practice in Russia

 		Breast Cancer Russia NCT04943497